Katherine Moldave, MBA

Katherine Moldave is the co-founder of AlcheraBio. She has extensive experience in business and strategic planning, marketing planning and strategy, technical communications, product management, and marketing communications in animal health, crop science, and technology.

Ms. Moldave is the AlcheraBio managing member with overall responsibility for post-marketing studies. Ms. Moldave co-authored Clinical Effectiveness and Safety of a New NSAID, Firocoxib: A 1,000 Dog Study, published in July 2006 in Veterinary Therapeutics. The paper is a report on a standard-setting post-marketing study AlcheraBio managed for a major animal health company. Along with Dr. Rhodes, Ms. Moldave has been a regular contributor to AnimalPharm newsletter and coauthored strategic white paper that has served as the impetus for the ongoing evolution of the Alliance for Contraception in Cats and Dogs.

Ms. Moldave graduated from Washington University in St. Louis and received her MBA from Fairleigh Dickinson University in New Jersey. Her experience includes 7 years at Merck and Merial (the animal health joint venture of Merck and sanofi-aventis) in the global marketing and strategic planning organization, and she successfully developed a previous communications business. She has a valuable ability to translate science to non-scientists that helps to bring project teams together and balances science and marketing.

Katherine is shown with her wonderful Dobie, Clio, who regrettably is no longer with us